AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Chronic Granulomatous Disease

Recent research efforts aimed at curing Chronic Granulomatous Disease.

Last updated

Chronic Granulomatous Disease

Overview

Chronic granulomatous disease (CGD) is a rare inherited immune disorder in which certain white blood cells—especially neutrophils—cannot generate the reactive oxygen chemicals needed to kill many bacteria and fungi. This leads to recurrent or severe infections, inflammatory disease such as colitis, and granulomas, which are inflammatory tissue masses that can obstruct organs. CGD may be X-linked, most often involving the CYBB gene and affecting males more severely, or autosomal recessive, including forms caused by NCF1 defects. Survival has improved substantially with modern care, but prognosis remains worse in people with little or no residual oxidase activity and in X-linked disease. GeneReviews: Chronic Granulomatous Disease

Current standard care is lifelong antibacterial and antifungal prevention, rapid treatment of infections, management of inflammation, and often interferon-gamma immunotherapy. Allogeneic hematopoietic stem-cell transplantation (HSCT)—replacement of the blood-forming system with donor stem cells—is the established curative treatment, particularly successful when performed early with a well-matched donor; however, it can cause graft failure, graft-versus-host disease, and other transplant complications. GeneReviews: Chronic Granulomatous Disease

Scope of Recent Research (2020–present)

Research since 2020 has been clinically active and increasingly focused on one-time autologous therapies: collecting a patient’s own blood-forming stem cells, correcting or adding the relevant gene outside the body, and reinfusing them after conditioning chemotherapy. The major questions are whether corrected long-term stem cells can engraft durably despite CGD-associated inflammation, whether gene editing can avoid unintended genomic changes, and whether these approaches can safely match or improve on donor HSCT. The field now has durable lentiviral gene-addition results in X-linked CGD and the first human evidence of prime editing in NCF1-related CGD, but these remain small early-phase studies rather than broadly available cures. Lentiviral gene therapy for X-linked CGD Prime editing for p47phox-deficient CGD

Major Breakthroughs and Emerging Therapies

Lentiviral gene addition for X-linked CGD. The most mature experimental strategy uses a lentiviral vector to insert a working copy of CYBB, which encodes gp91^phox, into a patient’s CD34-positive hematopoietic stem and progenitor cells. In the 2020 report of nine severely affected participants, six of seven survivors had stable corrected-neutrophil activity at 12 months, and six discontinued CGD-specific antimicrobial prevention; no evidence of vector silencing or clonal dysregulation was reported during the stated follow-up. Lentiviral gene therapy for X-linked CGD

Follow-on evidence has made clear that successful gene transfer alone is not enough: the patient’s stem-cell health before treatment strongly influences whether corrected cells persist. A 2023 phase I/II report in four people with X-linked CGD found stable engraftment and clinical benefit in two, while two progressively lost corrected cells. Single-cell RNA sequencing linked poor engraftment to inflammatory interferon signaling and depleted stem-cell populations, identifying a biological reason why patients with active, longstanding inflammation may have inferior outcomes. Stem-cell inflammation and CGD gene therapy

Prime editing for p47^phox-deficient CGD. Prime editing is a gene-editing approach designed to make a precise DNA change without creating the conventional double-strand DNA break used by standard CRISPR-Cas9 editing. PM359 corrects the common two-base “delGT” mutation in NCF1, which causes p47^phox-deficient CGD. In a 2025 peer-reviewed report, two adults received their own prime-edited CD34-positive cells after busulfan conditioning. Both showed prompt neutrophil and platelet recovery, restored NADPH oxidase activity within one month, and persistence of activity through six months and four months of follow-up, respectively; adverse events were consistent with busulfan conditioning. Prime editing for p47phox-deficient CGD

Gene editing beyond PM359. Researchers are also developing CRISPR-based approaches for both CYBB and CYBA forms of CGD, including insertion of a shortened CYBB DNA sequence intended to address many X-linked mutations with one design. A 2025 preclinical study found that conventional editing could produce off-target changes and chromosomal translocations that impaired engraftment in mice; use of a high-fidelity Cas9 enzyme improved this result, while a Cas9 nickase strategy showed no detectable off-target activity or translocations in the reported assays. Targeted gene editing of CYBA and CYBB

Lentiviral treatment for p47^phox-deficient CGD. A separate gene-addition route for NCF1 disease has progressed from preclinical work to a first-in-human study. Before clinical entry, investigators showed that a self-inactivating lentiviral vector restored neutrophil function in a p47^phox-deficient mouse model and in patient-derived cells transplanted into immunodeficient mice, without evidence of mutagenesis or tumorigenesis in their standardized safety studies. Preclinical lentiviral therapy for p47phox-deficient CGD

Clinical Trials and Experimental Approaches

The G1XCGD/OTL-102 lentiviral program for X-linked CGD is the principal completed early clinical gene-therapy experience. California’s stem-cell agency reports that 10 participants received the product: five had sustained gene expression for at least two years and became clinically well enough to discontinue CGD medicines, whereas four pediatric participants lost approximately 99% of gene marking within three to four months. The program’s long-term follow-up therefore supports durable benefit in some recipients but also underscores the central problem of inconsistent stem-cell engraftment. CIRM G1XCGD clinical trial award

PM359 was studied in the open-label, multicenter phase I/II PRIME-0101 trial (NCT06559176), sponsored by Prime Medicine. The registry lists an estimated enrollment of 12 and long-term follow-up through 2030, while the peer-reviewed report describes only two treated participants and states that further enrollment was stopped at the sponsor’s discretion for reasons unrelated to safety or efficacy. This discrepancy means the public registry should not be interpreted as evidence that additional patients are actively being dosed. PM359 trial record Prime editing for p47phox-deficient CGD

A second p47^phox program, SGX-001, is a first-in-human phase I/II trial sponsored by Somagenetix AG. It uses autologous CD34-positive cells transduced with a lentiviral vector encoding human NCF1. The study began on August 18, 2026, plans to enroll five pediatric and adult participants without a suitably matched sibling donor, and defines a biologic response as NADPH oxidase activity in at least 10% of peripheral-blood granulocytes at 12 months; no clinical outcomes have yet been reported. SGX-001 trial record

Methodologies and Scientific Approaches

Most curative research uses ex vivo autologous hematopoietic stem-cell therapy. CD34-positive stem and progenitor cells are mobilized into blood, collected by apheresis, modified with a lentiviral vector or gene editor, tested for quality and safety, and infused after chemotherapy creates marrow space. Researchers then measure restoration of the neutrophil oxidative burst with the dihydrorhodamine (DHR) assay, alongside blood-cell recovery, vector copy number, insertion-site patterns, infection frequency, inflammatory markers, and long-term persistence of corrected cells. PM359 trial record Lentiviral gene therapy for X-linked CGD

Preclinical work combines patient-derived CD34-positive cells, induced pluripotent stem-cell models, disease-model mice, and immunodeficient mice engrafted with human cells. Increasingly, studies use whole-genome or targeted assays for off-target edits and chromosomal rearrangements, as well as single-cell transcriptomics to identify stem-cell exhaustion and interferon-driven inflammatory states before treatment. These methods aim to predict which patients need inflammation control or modified conditioning before receiving a curative cell product. Stem-cell inflammation and CGD gene therapy Targeted gene editing of CYBA and CYBB

Leading Institutions and Funding

Major academic and clinical contributors include the U.S. National Institutes of Health (NIH), University College London and Great Ormond Street Hospital, UCLA, the NIH Clinical Center, University College London Hospitals, CHU Sainte-Justine in Montreal, and participating centers in Nashville and Vancouver. The PM359 clinical paper reports support from Prime Medicine as well as NIH intramural National Institute of Allergy and Infectious Diseases projects ZIA AI000644 and ZIA AI000645 and federal support through the National Cancer Institute. Prime editing for p47phox-deficient CGD

Industry programs include Prime Medicine’s PM359 and Somagenetix’s SGX-001, while the earlier X-linked lentiviral work was advanced through Genethon, Orchard Therapeutics, UCLA, NIH, and international transplant centers. The California Institute for Regenerative Medicine awarded $6,846,964 to Donald Kohn at UCLA for the G1XCGD phase I/II effort, illustrating the importance of public funding in an ultra-rare disease with limited commercial trial populations. CIRM G1XCGD clinical trial award

Strengths, Limitations, and Challenges

The strongest evidence is that replacing or repairing the blood-forming system can restore NADPH oxidase function and prevent new CGD-related infections. Autologous approaches avoid donor matching and graft-versus-host disease, and prime editing may offer the additional advantage of correcting a disease-causing mutation at its natural genomic location rather than adding a gene semi-randomly. The two PM359 recipients and the durable subgroup in the X-linked lentiviral studies are important proof-of-concept milestones, not yet definitive evidence of long-term cure. Prime editing for p47phox-deficient CGD CIRM G1XCGD clinical trial award

The principal limitations are small participant numbers, short follow-up for newer editors, toxicity from conditioning chemotherapy, manufacturing complexity, and unequal access to specialized transplant and gene-therapy centers. Inflammation is a particularly important scientific challenge: it can exhaust a patient’s own stem cells and reduce engraftment, while conventional CRISPR-Cas9 editing can introduce off-target changes or chromosomal rearrangements unless carefully engineered. Finally, each platform initially addresses only selected genetic subtypes, so a universal autologous cure for all forms of CGD remains an unfinished goal. Stem-cell inflammation and CGD gene therapy Targeted gene editing of CYBA and CYBB

Outlook and Future Directions

As of October 12, 2026, donor HSCT remains the only established curative option, but autologous genetic therapies have crossed an important threshold from theory to human proof of concept. The next milestones are durable multi-year outcomes from prime editing, safety monitoring for insertional mutagenesis and unintended edits, enrollment and first results from SGX-001, and strategies that suppress inflammation or improve stem-cell fitness before collection and conditioning. If those studies show stable correction without major late toxicity in larger pediatric and adult cohorts, CGD could become one of the first primary immune deficiencies with multiple personalized, donor-free curative options. GeneReviews: Chronic Granulomatous Disease SGX-001 trial record

References

Don't see your disease? Request a report